^
    Back
    Association details:
    Biomarker:IL10 elevation
    Cancer:Peripheral T-cell Lymphoma
    Regimen: (vincristine + prednisone + doxorubicin hydrochloride + cyclophosphamide)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Front Oncol
    Title:

    Increased Serum Level of Interleukin-10 Predicts Poor Survival and Early Recurrence in Patients With Peripheral T-Cell Lymphomas

    Published date:
    10/13/2020
    Excerpt:
    ...most patients received combination chemotherapy, including cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) or CHOP-like regimens...increased serum levels of IL-10 at diagnosis is related to the survival and early recurrence of PTCL patients. IL-10 ≥3.6 pg/ml is significantly correlated with lower CR rate, higher recurrence rate and lower OS rate. Furthermore, univariate and multivariate analysis indicated that IL-10 ≥3.6 pg/ml is an independent prognostic factor.
    DOI:
    10.3389/fonc.2020.584261